WALTHAM, Mass • 2021-11-02

BostonGene Announces Publication in Cancer Research

5 min to read

Study Reveals Oncogenic HSP90 Supports Metabolism in B-cell Lymphoma Cells and Patients with Diffuse Large B-cell Lymphoma

Study Reveals Oncogenic HSP90 Supports Metabolism in B-cell Lymphoma Cells and Patients with Diffuse Large B-cell Lymphoma



WALTHAM, Mass, November 2, 2021

BostonGene Corporation, a biomedical software company committed to defining optimal precision medicine-based therapies for cancer patients today announces a new publication in the peer-reviewed scientific journal Cancer Research, a journal of the American Association for Cancer Research.  The study, performed in collaboration with Weill Cornell Medicine and titled “Oncogenic HSP90 facilitates metabolic alterations in aggressive B-cell lymphomas, details the role of oncogenic heat shock protein 90 (HSP90) to support metabolic pathways in B-cell lymphoma cells and in patients with diffuse large B-cell lymphoma (DLBCL).

This study evaluated the role of oncogenic HSP90 in regulating cytosolic metabolic pathways in proliferating B-cell lymphoma cells. Oncogenic HSP90 was shown to facilitate the organization of metabolic enzymes into non-membrane-bound functional compartments. BostonGene’s analysis enabled reconstructing the microenvironment in lymphoma expressing a double hit signature, an indicator of aggressive lymphoma with high MYC activity. This analysis showed that alterations to the MYC metabolic program affected immune infiltration, providing insights into improving lymphoma immunity via MYC. It was also observed, under experimental conditions, which conserved cellular proteostasis, oncogenic HSP90 coordinated and sustained multiple metabolic pathways required for energy production and maintenance of cellular biomass as well as for secretion of extracellular metabolites.

“The goal of the study was to further understand metabolic regulation of cellular proteostasis in patients with DLBCL,” said Leandro Cerchietti, M.D., Associate Professor of Medicine and a member of the Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine. “The encouraging results of this research study demonstrate oncogenic HSP90 is tightly linked to the preservation of cellular biomass providing a novel mechanism of activity for HSP90 inhibitors.”

“These findings underscore the pivotal role of oncogenic HSP90 in the regulation of metabolic pathways in lymphoma, revealing a potential therapeutic vulnerability in B-cell lymphoma,” said Nathan Fowler, MD, Chief Medical Officer at BostonGene. “We are pleased to support Weill Cornell Medicine in their research efforts to find optimal therapeutic treatments for patients with DLBCL.”

About BostonGene Corporation

BostonGene has a mission to provide transformative, AI-integrated molecular analytics and biomarker discovery for precision matching of therapies to improve the lives of patients living with cancer and other immune-related diseases. BostonGene’s service model provides customized client solutions using a multi-omic approach prioritized for real-world impact, including optimized standard-of-care therapies, accelerated research and cost-effective, measurable results. BostonGene’s tests reveal key drivers of each patient’s unique disease profile, including an in-depth profile of the immune microenvironment, actionable mutations, biomarkers of response to diverse therapies, and recommended therapies. Through these comprehensive analyses, BostonGene’s tests generate a personalized roadmap for therapeutic decision-making for each patient. For more information, visit BostonGene at http://www.BostonGene.com.

Erin O’Reilly

Senior Director

+1-617-283-2285

Erin.Oreilly@BostonGene.com